GlassScriptPhysician profile
Rajani Rangray
NPI 1023270261
$15,322.46
in general payments reported to CMS, 2019-2025
29 companies · $5,655 in 2025
The $5,655 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $270 · 2021: $506 · 2022: $498 · 2023: $1,194 · 2024: $6,103 · 2025: $5,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,480 · Food and Beverage: $6,373 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,480.00 |
| Food and Beverage | $6,372.54 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $6,817.29 | 2022-2025 | Ocaliva |
| Gilead Sciences, INC. | $1,510.86 | 2019-2025 | |
| Abbvie INC. | $1,392.92 | 2019-2025 | |
| Janssen Biotech, INC. | $1,098.27 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Boston Scientific Corporation | $770.94 | 2019 | |
| Genzyme Corporation | $663.50 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $566.90 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $386.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $291.94 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.42 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $251.37 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $239.66 | 2019-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $221.61 | 2024-2025 | Ibsrela |
| Celgene Corporation | $161.96 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $115.22 | 2025 | Iqirvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $83.13 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $77.52 | 2023-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $67.75 | 2021-2024 | |
| Amgen INC. | $54.03 | 2020-2025 | Uplizna |
| Celltrion USA INC. | $47.81 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $35.15 | 2023-2025 | Rebyota |
| Braintree Laboratories, INC. | $34.27 | 2019-2023 | Suflave |
| Daiichi Sankyo INC. | $33.97 | 2023-2024 | Injectafer |
| Organon LLC | $23.58 | 2024 | |
| Fresenius Kabi USA, LLC | $19.13 | 2023 | Idacio |
| Alexion Pharmaceuticals, INC. | $17.96 | 2022 | |
| Merck Sharp & Dohme LLC | $17.73 | 2022 | |
| Welch Allyn | $16.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.20 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajani Rangray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.